John Rubino, MD
Internal Medicine · Raleigh, NCNPI 1962543280
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Pfizer at 56.2% of the total. Reporting peaked in 2023 at $6,389 and has fallen 80.4% since, to $1,252 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $51.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Amgen$1K
- Modernatx, Inc.$1K
- AbbVie$479
- Novo Nordisk$462
- AstraZeneca$327
- plus $2K from 36 others
Across 1,802 payments — averaging $7268.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4.3M
- Bavarian Nordic A/s$1.5M
- Eli Lilly$1.3M
- Biontech SE$1.2M
- Modernatx, Inc.$1.1M
- Regeneron$916K
- plus $2.7M from 22 others
What the payments were for
- Consulting fees$5,84145%
- Travel & lodging$2,61620%
- Food & beverage$4,55635%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$13,033 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 16 | $156,036 |
| OzempicSemaglutide | 108 | $120,793 |
| EliquisApixaban | 87 | $105,126 |
| JardianceEmpagliflozin | 77 | $89,945 |
| Repatha SureclickEvolocumab | 116 | $86,119 |
| CreonLipase/Protease/Amylase | 22 | $49,459 |
| JanuviaSitagliptin Phosphate | 35 | $39,544 |
| MyrbetriqMirabegron | 42 | $36,463 |
| MounjaroTirzepatide | 24 | $32,332 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $30,044 |
| Emgality PenGalcanezumab-Gnlm | 24 | $28,024 |
| TrulicityDulaglutide | 22 | $26,385 |
| NexletolBempedoic Acid | 26 | $22,638 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $21,615 |
| TradjentaLinagliptin | 12 | $18,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $120 | $130,130107 claims |
| Novo NordiskOzempic, Novolog Mix 70-30 | $462 | $124,207120 claims |
| PfizerEliquis | $7,327 | $105,12687 claims |
| Lilly USA, LLCMounjaro, Trulicity | $128 | $58,71746 claims |
| AbbVieCreon, Synthroid | $479 | $57,083117 claims |
| MerckJanuvia, Janumet Xr | $192 | $51,34854 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $115 | $38,54649 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $36,46342 claims |
| Esperion Therapeutics, Inc.Nexletol | $64 | $22,63826 claims |
| AstraZenecaFarxiga | $327 | $17,76914 claims |
| NovartisEntresto | $121 | $13,43515 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $7,352528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- Bhakti PaulRaleigh$536K
- Christina CraterRaleigh$330K
- Charles CookRaleigh$228K
- Anthony AzziRaleigh$81K
- Dishita PandyaRaleigh$71K
- Afreen ShariffRaleigh$66K
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Mary KlotmanDurham$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.